INS and metabolic syndrome: In contrast with the aforementioned studies, Homma et al. demonstrated that treatment with spironolactone, but not with eplerenone, was associated with an increase in plasma blood glucose in basal conditions and after oral glucose tolerance test, without changes in the levels of insulin and adiponectin in a rat model of metabolic syndrome [93].